Leukaemia cells can transform into non-cancerous cells through epigenetic changes

November 13, 2019

All the tissues of our body have the same DNA, but they perform very different functions and have very different aspects. For example, a lymphocyte and a neuron share the same genetic material, but they play very different tasks, and their appearance under the microscope is entirely dissimilar. What gives cells their own identity and differentiates them is their particular epigenetics, the chemical modifications that control gene expression. It has been accepted for decades that the semblance of a tumor cell (its "phenotype") is discordant to the look of its original normal cell. Furthermore, recently, it has been discovered that an extraordinary phenomenon can occur in cancer: one type of cell may become a different type of cell.

This process is known as transdifferentiation and is used, for example, by human tumor cells as a strategy to escape from a drug designed to kill them. Today, an article published by researchers of the group of Dr. Manel Esteller, Director of the Josep Carreras Leukaemia Research Institute, ICREA researcher and professor of the University of Barcelona, describe how a leukaemia type B cell can transform into a different cell, a macrophage, changing its epigenome and consecutively getting a new cellular identity.

"We began with this work stating that if DNA methylation is the best known and validated epigenetic mark that confers its appearance to cells, such chemical modification could be directly involved in enabling tissue transdifferentiation. By using a cellular model of lymphoblastic leukaemia B cells that we could transform into macrophages, we obtained a high-resolution epigenetic profile of each step of the transdifferentiation process. This transdifferentiation example is interesting since it doesn't only change the cell type, but also its behavior. While a cancerous cell multiplicates fast, a highly differentiated cell doesn't proliferate at all" -comments Dr. Esteller about the research published in Leukaemia, and adds: "We saw that the epigenome of the leukaemic cell changes when it transdifferentiates. Chemically, the cells disguise their epigenome to resemble a macrophage. The changes occur in thousands of sites of the genetic material, even between chromosomal regions far apart from each other, which approach to activate those genes that provide a distinct appearance to the cell. Applications of this discovery could be avoiding the emergent resistance to cancer treatments with drugs: if we blocked the epigenetic changes identified, leukaemia cells could not select the transdifferentiation strategy to escape from the antitumor effect of the drug, and the therapy would be more effective." -Concludes the researcher."
-end-


Josep Carreras Leukaemia Research Institute

Related Leukaemia Articles from Brightsurf:

An area of the brain where tumor cells shelter from chemotherapy in childhood leukaemia
Sometimes, the central nervous system harbours tumour cells that elude treatment and thus become one of the main sources of relapse.

Feline leukaemia virus infection: A clinical and epidemiological enigma
Feline leukaemia virus (FeLV) is a gammaretrovirus that occurs worldwide in domestic cats, as well as small wild cats.

Decades old mystery in leukaemia treatment solved
A research team led by the University of Kent and Goethe-University Frankfurt am Main, has solved an almost 40-year old mystery in leukaemia therapy and the drug nelarabine, thanks to studying levels of enzyme SAMHD1.

Treating leukaemia more effectively
Acute lymphoblastic leukaemia (ALL) is the most common kind of cancer in children.

Targeting stem cells: The path to curing poor-prognosis leukaemia
Researchers have been investigating what they believe to be the root cause of treatment resistance, leukaemia stem cells, and have now hit upon a new therapeutic approach that works by targeting these cells.

Promising new approach to treating some of the worst types of leukaemia
'New therapeutic approaches are desperately needed for MLL-r leukaemia,' said Professor Richard Lock, Head of the Blood Cancers Theme at Children's Cancer Institute, Australia.

Leukaemia cells can transform into non-cancerous cells through epigenetic changes
Researchers of the Josep Carreras Leukaemia Research Institute discover that a leukaemic cell is capable of transforming into a non-cancerous cell through epigenetic changes.

Published a clinical guide for the genomic diagnosis of Myelodysplastic Syndromes and Chronic Myelomonocytic leukaemia
A collective work between researchers from 8 research centres and hospitals in Spain, coordinated by Francesc Solé of the Josep Carreras Leukaemia Research Institute (IJC), and Esperanza Such, of the University and Polytechnic Hospital de la Fe describes the recommendations of use of the Next Generation genome Sequencing (NGS) in the diagnosis of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML).

Old cells, new tricks -- important clue to AML diagnosis and cure discovered
Around 22,000 people will be diagnosed this year in the US with acute myeloid leukemia (AML), the second most common type of leukemia diagnosed in adults and children.

New drug providing hope for babies with aggressive Acute Lymphoblastic Leukaemia
A breakthrough new drug is providing hope to tiny babies at risk of dying from an aggressive form of Acute Lymphoblastic Leukaemia and could help all cancer patients.

Read More: Leukaemia News and Leukaemia Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.